Molecularly-targeted therapies: hope, and challenges

This is a riveting three-part series about new approaches to treating metastatic melanoma. The road to progress is filled with peaks and valleys, and there's a long way to go. The challenges to targeting the molecular "engines" of proliferating cancers are immense. The NYTimes piece offers a sense of the emotional roller coasters faced by the physicians leading early clinical trials and the patients clinging to the few extra months they have to live.